Allianz Asset Management’s Theravance Biopharma TBPH Stock Holding History

Allianz Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-46,499	Closed	-$1.71M	–	2689
2017 Q1	$1.71M	Hold	46,499	–	–	﹤0.01%	2057
2016 Q4	$1.48M	Hold	46,499	–	–	﹤0.01%	2077
2016 Q3	$1.69M	Buy	+46,499	New	+$1.29M	﹤0.01%	2048

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Allianz Asset Management's TBPH Position: Q2 2017 in Review

Allianz Asset Management sold out of Theravance Biopharma (TBPH) in Q2 2017, closing a stake of 46,499 shares — an estimated $1.71M sold.

Allianz Asset Management first reported a position in TBPH in Q3 2016 and held it in 3 quarters. The position peaked at $1.71M in Q1 2017. 94 funds tracked by Wall St. Rank hold TBPH as of Q2 2017.

Allianz Asset Management reported no remaining Theravance Biopharma position as of Q2 2017 after selling out during the quarter.
Allianz Asset Management sold 46,499 Theravance Biopharma shares in Q2 2017, an estimated $1.71M.
Allianz Asset Management first reported a position in Theravance Biopharma in Q3 2016 and held it in 3 quarters.
Allianz Asset Management's Theravance Biopharma position peaked at $1.71M in Q1 2017.
94 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2017.

Based on Allianz Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.